Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117819 · ClinicalTrials.gov registry record · Phase 2
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 232
- Enrollment target
NCT00117819 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 232 participants.
The verdict
NCT00117819, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 232 participants
- Enrollment target
Study Summary
This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter density. The imaging data coupled with family history and environmental exposure data may provide important information about potential risk factors for parkinsonian syndrome.
Interventions
- DRUG [123I]ß CIT and SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2001-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117819
The ClinicalTrials.gov registry entry for NCT00117819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I]ß CIT and SPECT imaging is the first listed.
NCT00117819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117819 about?
NCT00117819 is a clinical study titled "A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease". This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will h...
What is the current status of trial NCT00117819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 232 participants. The study started on 2001-03. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00117819?
The interventions under investigation include: [123I]ß CIT and SPECT imaging (DRUG).
Who is sponsoring clinical trial NCT00117819?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.